Table 2 Clinicopathological characteristics and comparison of clinicopathological characteristics with mrEMVI status
Clinicopathological characteristics | Total | mrEMVI (−) | mrEMVI (+) | P |
|---|---|---|---|---|
n = 72 (100%) | n = 47 (65.3%) | n = 25 (34.7%) | ||
Age, mean ± SD | 60 ± 10 | 61 ± 10 | 58 ± 10 | 0.214a |
Gender | 0.537b | |||
Male | 41 (56.9%) | 28 (59.6%) | 13 (52.0%) | |
Female | 31 (43.1%) | 19 (40.4%) | 12 (48.0%) | |
Tumour location# | 0.355b | |||
Lower | 13 (18.1%) | 10 (21.3%) | 3 (12.0%) | |
Middle | 32 (44.4%) | 22 (46.8%) | 10 (40.0%) | |
Upper | 27 (37.5%) | 15 (31.9%) | 12 (48.0%) | |
Tumour size (cm), median (range) | 3.0 (0.3–6.0) | 2.9 (0.3–6.0) | 3.5 (1.8–6.0) | 0.011c* |
Differentiation | 0.234d | |||
Well | 1 (1.4%) | 1 (2.1%) | 0 (0.0%) | |
Moderate | 60 (83.3%) | 41 (87.2%) | 19 (76.0%) | |
Poor | 11 (15.3%) | 5 (10.6%) | 6 (24.0%) | |
Pathological T stage | 0.010b* | |||
T1–2 | 19 (26.4%) | 17 (36.2%) | 2 (8.0%) | |
T3–4 | 53 (73.6%) | 30 (63.8%) | 23 (92.0%) | |
Pathological N stage | 0.001b* | |||
N0 | 36 (50.0%) | 30 (63.8%) | 6 (24.0%) | |
N1–2 | 36 (50.0%) | 17 (36.2%) | 19 (76.0%) | |
Synchronous distant metastasis | 0.426b | |||
Negative | 51 (91.1%) | 35 (94.6%) | 16 (84.2%) | |
Positive | 5 (8.9%) | 2 (5.4%) | 3 (15.8%) |